To read the full story, subscribe or sign in.

I-Mab licenses rights for diabetes treatment to CSPC for $21.7M

Dec. 24, 2018

HONG KONG – I-Mab Biopharma (Shanghai) Co. Ltd. out-licensed China rights to its long-acting glucagon-like peptide-1 (GLP-1) Fc protein, known as TG-103, to treat diabetes to CSPC Pharmaceutical Group Co. Ltd. for ¥150 million (US$21.7 million).

BioWorld

Today's news in brief

BioWorld

CROI 2026: Neurodegeneration, the challenge of aging with HIV

BioWorld

Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...

Depression concept with human, broken brain and heavy rain

CROI 2026 highlights depression and cognitive vulnerability in HIV

BioWorld

The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 3, 2026

University of Southern California reports new MAPT aggregation inhibitors

BioWorld Science

The University of Southern California has identified (2-oxo-2H-chromen-3-yl) scaffold-based carboxamide analogues acting as potent microtubule-associated protein...